Isogenica Ltd. Biologics discovery overview

Similar documents
Custom Antibodies & Recombinant Proteins

HuCAL Custom Monoclonal Antibodies

HuCAL Custom Monoclonal Antibodies

Genes to Proteins to Antibodies

3 months 1.5 months 1.5 months. 1 month

CUSTOM ANTIBODIES. Fully customised services: rat and murine monoclonals, rat and rabbit polyclonals, antibody characterisation, antigen preparation

Chapter 5: Organization and Expression of Immunoglobulin Genes

Recombinant Antibody Fragments, Brochure

MAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères Evry Cedex. is involved at each stage of your project

LabGenius. Technical design notes. The world s most advanced synthetic DNA libraries. hi@labgeni.us V1.5 NOV 15

KMS-Specialist & Customized Biosimilar Service

Next generation sequencing and proteomics. to study the antibody repertoire. and generate monoclonal antibodies

GenScript Antibody Services

GenBank, Entrez, & FASTA

Guidance for Industry

Interaktionen von Nukleinsäuren und Proteinen

Biologics Drug Discovery: Steps to producing an antibody drug candidate Frank Fan, M.D. Ph.D.

Avacta Group plc. Innovation for global health. Interims results for the period ended 31 st January Avacta Group plc

GenScript Antibody Services

Bio-Reagents Gene synthesis Peptide Synthesis Protein Expression Antibody Production. Life Science Products and Services

Dr.ssa Maria Luisa Nolli CEO

Transcription and Translation of DNA

From DNA to Protein. Proteins. Chapter 13. Prokaryotes and Eukaryotes. The Path From Genes to Proteins. All proteins consist of polypeptide chains

Catalent Biologics & Clinical Supplies The SMART Solution

Therapeutic Systems Immunology

Some terms: An antigen is a molecule or pathogen capable of eliciting an immune response

Luca Romagnoli, Ph.D. Business Development Manager

TCRG TCRA/D IGH IGK/L

Ms. Campbell Protein Synthesis Practice Questions Regents L.E.

Antibody Structure, and the Generation of B-cell Diversity CHAPTER 4 04/05/15. Different Immunoglobulins

Figure 4.1: Gel picture showing Generation of HIV-1subtype C codon optimized env expressing recombinant plasmid pvax-1:

How many of you have checked out the web site on protein-dna interactions?

Your partner in immunology

LESSON 3: ANTIBODIES/BCR/B-CELL RESPONSES

Making the switch to a safer CAR-T cell therapy

Vector NTI Advance 11 Quick Start Guide

Introduction to Bioprocessing

13.2 Ribosomes & Protein Synthesis

博 士 論 文 ( 要 約 ) A study on enzymatic synthesis of. stable cyclized peptides which. inhibit protein-protein interactions

Integrated Protein Services

Application Guide... 2

Analyzing antibody sequence for recombinant antibody expression. Hangxing Yu, Ph.D Senior Scientist, GenScript May 20, 2015

Lecture 3: Mutations

Expression and Purification of Recombinant Protein in bacteria and Yeast. Presented By: Puspa pandey, Mohit sachdeva & Ming yu

BBSRC TECHNOLOGY STRATEGY: TECHNOLOGIES NEEDED BY RESEARCH KNOWLEDGE PROVIDERS

Recombinant DNA Technology

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)

CCR Biology - Chapter 9 Practice Test - Summer 2012

INDUSTRY OVERVIEW. Our business segments. (ii) Global drug development service market Preclinical drug development services

IMBB Genomic DNA purifica8on

TIANquick Mini Purification Kit

Lecture Series 7. From DNA to Protein. Genotype to Phenotype. Reading Assignments. A. Genes and the Synthesis of Polypeptides

Cell Discovery 360: Explore more possibilities.

Molecular Cloning, Product Brochure

Chapter 2 Antibodies. Contents. Introduction

Current Motif Discovery Tools and their Limitations

'LVFXVVLRQ $UUD\HGF'1$H[SUHVVLRQOLEUDULHV 5RERWWHFKQRORJ\DQGDUUD\HGOLEUDULHV

T cell Epitope Prediction

HiPer RT-PCR Teaching Kit

Recombinant DNA & Genetic Engineering. Tools for Genetic Manipulation

MultiQuant Software 2.0 for Targeted Protein / Peptide Quantification

Name Date Period. 2. When a molecule of double-stranded DNA undergoes replication, it results in

LC-MS/MS STRATEGIES FOR QUANTIFICATION OF THERAPEUTIC ANTIBODIES TO SUPPORT CLINICAL

Molecular Genetics. RNA, Transcription, & Protein Synthesis

Classic Immunoprecipitation

Bispecific antibodies with native chain structure

ProteinPilot Report for ProteinPilot Software

A customizable ADCC assay service for antibodies & fusion proteins.

Why is FTO important?

RNA & Protein Synthesis

Enzymes: Practice Questions #1

DNA and Forensic Science

Antibody Function & Structure

ELITE Custom Antibody Services

HCS Exercise 1 Dr. Jones Spring Recombinant DNA (Molecular Cloning) exercise:

Advanced BioDesign Outlines Solutions. Antibody Overview. by Advanced BioDesign. Project Start. Immunogenicity. Selecting Your Antigen

June 09, 2009 Random Mutagenesis

Towards Well-Defined ADCs (Antibody Drug Conjugates)

A Novel Bioconjugation Technology

2. True or False? The sequence of nucleotides in the human genome is 90.9% identical from one person to the next. False (it s 99.

Genomic DNA Clean & Concentrator Catalog Nos. D4010 & D4011

Outline. Market & Technology Trends. LifeTein Technology Portfolio. LifeTein Services

Bioinformatics Grid - Enabled Tools For Biologists.

SICKLE CELL ANEMIA & THE HEMOGLOBIN GENE TEACHER S GUIDE

Forensic DNA Testing Terminology

restriction enzymes 350 Home R. Ward: Spring 2001

Development and validation of neutralising anti-drug antibody (Nabs) assays

Lecture 4. Polypeptide Synthesis Overview

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Q5B

Institutional Partnership Program

Integrated Protein Services

DNA Replication & Protein Synthesis. This isn t a baaaaaaaddd chapter!!!

1 Mutation and Genetic Change

Recombinant DNA and Biotechnology

The sequence of bases on the mrna is a code that determines the sequence of amino acids in the polypeptide being synthesized:

CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS

Stefanie Urlinger, Director R&D, MorphoSys AG. Making fully human antibody drugs from synthetic antibody libraries

Structure and Function of DNA

Improving GS-CHO Cell Line Selection: Reducing Time to Clinic

Analysis of the adaptive immune response to West Nile virus

Transcription:

Isogenica Ltd Biologics discovery overview 1

Isogenica Specialist antibody and peptide display company Based in Cambridge at the heart of UK Biotech Expertise in protein and peptide engineering since 2001 Offering a range of leading edge library and display technologies Flexible partnering models 2

Key components for antibody libraries Library design Avoid liabilities Incorporate advantages 100 90 80 70 60 50 40 30 20 10 0 Library generation Library synthesis with Colibra Design-to-functional library 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Y W V T S R Q P N M L K I H G F E D C A Library display Proprietary CIS Display (cell-free) Eukaryotic display (H2 2015) Phage display 3

Library diversity from natural repertoire 10 14 Theoretical IgG naïve V(D)J repertoire 10 13 10 12 10 11 Total B-cells in an adult 10 10 10 9 10 8 10 7 Non-redundant PBMC naïve clones/adult 10 6 10 5 Non-redundant PBMC IgG clones/adult 4

Diversity vs functionality Natural repertoire libraries give high functionality but low diversity Poor quality synthetic libraries give high diversity but low functionality because of design issues, Random synthetic diversity is not tolerated in many positions in the CDRs Further aggravated as the length of the CDRs increase and build issues Conventional degenerate oligos lead to coding defects (stop codons, frameshifts, etc) Tri-nucleotide phosphoramidate (TRIM) oligos lack fine control of amino acid representation 5

Analysis of the natural repertoire Through analysis of the natural repertoire we now: Understand the natural positional bias in amino acid use Understand how CDR length influences this bias Understand which are the optimal frameworks for use This results in the capacity to design synthetic libraries with high functional diversity 6

Translating the theoretical library into the library design Optimal functional diversity Optimal framework choice Converts theoretical library into practical library design Optimal biochemical characteristics Optimal dispersion of diversity 7

Colibra technology Blunt ended ligation methodology Codons selected for optimal performance Integration with next generation sequencing for full functional and sequence based quality control Automation for scale-up CODON LIBRARY ACCEPTOR FRAMEWORK 5 3 ----- ----- 3 5 5 P 3 3 Ligate and Amplify 5 5 3 ----- ----- Digest with Type IIS RE 3 5 5 3 Repeat, next cycle 3 5 8

Advantages of Colibra Enables precise library build, humanisation, affinity maturation, natural repertoire mimicry Colibra TM allows codon pairs to be defined and accurately incorporated Reduce liabilities (isomerisation, deamidation, glycosylation, protease sites, oxidation sites, cysteine) Colibra TM libraries are true to the original design Improves efficiency of antibody discovery projects 9

CIS display cell-free DNA display RepA is a naturally occurring protein that binds its own DNA sequence allowing it to act as a linker between phenotype and genotype 10

Advantages of CIS display Bind to target No transformation, unlike phage display DNA-based system, not RNA Cis-activity of DNA-binding protein RepA Libraries up to 10 13 expressed in vitro stable protein-dna complexes Protein-DNA complexes subjected to affinity selection Eluted complexes regenerated by PCR Optimal ligands after 3-5 successive rounds Robust methodology and easy technology transfer 11

V HH antibody fragment Single domain of camelid heavy chain only antibody Maintains specificity and affinity of parent antibody Validated as therapeutic in clinical trials Small (12-15 kda) High ph and temperature stability Simple, cost-effective manufacturing Ideal for ADC and multivalent formatting heavy chain IgG 12

Conventional route to generating V HH s heavy chain IgG Immunise a llama Extract blood Clone PCR Minimum 10 weeks work Labour intensive Accessed 10 6-10 7 diversity 13

Using the llamda TM system in CIS display Integrating: Powerful design Precision built through Colibra CIS display automatable in vitro system Library size > 10 12 unique domains (a million llamas in a tube) Hits generated in 4-6 weeks Nanomolar affinities from naïve selections 14

Synthetic human scfv libraries: Xab TM system Built through Colibra TM IgG conversion scfv Operated in phage display Available for service and licensing VH VL VH CDR1 CDR2 CDR3 CDR1 CDR2 CDR3 CDR1 CDR2 CDR3 CDR1 CDR2 CDR3 natural synthetic natural natural synthetic synthetic natural natural synthetic natural synthetic synthetic VL Libraries Athos Porthos Aramis Tested in phage 3 sub-libraries 3 sub-libraries 2 sub-libraries synthetic synthetic 15

4D Fab TM library construction - 2015 IgG conversion Fab Design by world class expertise in computational immunology Best-in-class functionality expected to be >Ylanthia (Morphosys) Fabrication initiated Early partnerships sought 16

Partnership in biologics discovery NextGen synthetic antibody libraries Discovery technologies VHH, scfv, Fab Maximise functional diversity Range of display technologies Scaffold and peptide libraries available Partnering CIS display Phage display IgG conversion Next generation sequencing Bioinformatics Analytical screening Discovery partnerships Lead optimisation partnerships Access to proprietary libraries Access to display technologies Cell based screens Flow cytometry / Cell sorting Affinity determination Biophysical analyses 17

Isogenica Ltd Biologics discovery overview 18